Public Perceptions of the Food and Drug Administration's Regulatory Authority Over Synthetic Nicotine on Twitter: Observational Study.

What Was Tested

Researchers studied Therapeutic nicotine (patch, non-peptide) in this observational study publication.

This study aims to examine the public perceptions of the Omnibus Bill that regulates synthetic nicotine products as tobacco products on Twitter (rebranded as X).

The longitudinal trend was used to examine the discussions related to the bill over time.

Why It Was Studied

The Omnibus Budget Bill, known as H.

R. 2471, passed through Congress on March 10, 2022, and was eventually signed by President Biden on March 15, 2022.

How the Study Was Run

Through the X streaming application programming interface, the researchers collected and identified 964 tweets related to the Omnibus Bill on synthetic nicotine between March 8, 2022, and April 13, 2022.

An inductive method was used for the content analysis of related tweets.

By hand-coding 200 randomly selected tweets by 2 human coders respectively with high interrater reliability, the codebook was developed for relevance, major topics, and attitude to the bill, which was used to single-code the rest of the tweets.

What Was Measured

The subject headings attached to it are United States, United States Food and Drug Administration, Social Media, Public Opinion and Nicotine.

The authors tagged it with the keywords FDA, Twitter, omnibus and synthetic nicotine.

What This Means in Plain Language

This is an observational study of Therapeutic nicotine (patch, non-peptide).

The abstract goes on to report its results in about 8 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2024 (JMIR formative research), a journal based in Canada.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.